GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for INTERBLEED

INTERBLEED

Official Title

Study of risk factors for gastrointestinal bleeding and of the determinants of non-fatal and fatal cardiovascular events after gastrointestinal bleeding in patients receiving antithrombotic therapy for cardiovascular prevention

Status

Ongoing

Overview

Antithrombotic therapies are effective for prevention of cardiovascular (CV) events but cause bleeding. Emerging evidence indicates that extra-cranial bleeding is just as important as myocardial infarction as a marker of risk for subsequent non-fatal and fatal CV events, but this issue has not been prospectively studied. If the association between bleeding and CV events is causal, prevention of bleeding, by targeting the risk factors, and prevention of the complications of bleeding, by targeting the causal pathways, could substantially reduce the burden of bleeding-related CV events.

Study Design

Multicenter, two component observational study: standardized case-control study and prospective study

Primary Endpoint

Composite of MI, stroke and death

Number of Patients

5000

Number of Sites

26

Number of Countries

7

Study Period

2015-2020

Principal Investigator

Dr. John Eikelboom, Dr. Jackie Bosch

Program Manager

Jessica Tyrwhitt

Research Coordinator

Preston Thompson

Collaborators

Heart and Stroke Foundation, Bristol-Myers Squibb, Daiichi Sankyo